Exploitation is a crucial activity of BRAINTEASER as it connects the results of the project to their subsequent market commercialization, aiming at a broader reach to the ALS and MS community.
Within the Exploitation activities, a series of Focus Group workshops has been organized by BRAINTEASER with external relevant stakeholders, with the aim of enlarging the project’s vision on users and market needs, obtaining additional requirements to accompany the go-to-market strategy towards the most suitable exploitation routes.
The first workshop, held on February 1st, 2022, titled Suitable exploitation routes co-design, offered an overview of the BRAINTEASER project as a whole, spotting a light on the apps and clinical tools that were under development.
The second workshop, held on February 21st, 2023, titled How to maximise the use and value of healthcare data, provided an update on the ongoing project activity, directing on the great importance of quality data as fuel for AI-based solutions exploitation.
The third focus group, held on Dec 11th, 2023, titled AI-based solutions for patients and health professionals, dealt with the interactive tools being designed to collect information from the patient and to provide personalized feedback, and the underlying data infrastructure.
The fourth focus group, held on September 17th, 2024, titled AI models for preventive medicine and early risk prediction, provided the latest results about the AI models designed and developed by BRAINTEASER partners.
Patient and clinician representatives, IT and pharma industry professionals, policy makers and regulatory experts, and ethical and communication authorities from all around Europe have been engaged in these dynamic meetings, implemented by the principles of participatory design, to assess and enhance the BRAINTESER solutions and its exploitation approach.
Great importance has been stressed by the participants to the involvement of the patient communities to increase knowledge and trust, the scalability of the solution to satisfy the growing needs, and the potential benefits for biotech companies to design and test new treatments, while particular attention need to be dedicated to the reliability of the data, the evolving regulatory landscape following the new EU AI Act, and the fragmentation of the national healthcare systems within EU.
The project’s Exploitation Strategy will be showcased at the BRAIN INNOVATION DAYS in Brussels on 13-14 November 2024, during the session “Harnessing AI for Brain Health: Lab to Market to Society,” organised by BRAINTEASER.
In March 2025, the fifth and final Focus Group workshop will present the integration of the BRAINTEASER AI Solution into the InSilicoTrials cloud-based platform to enhance access for pharmaceutical and biotech companies.
The completed BRAINTEASER Exploitation Strategy and related Plan will be officially presented at the project’s conclusion in June 2025.
